跳转至内容
Merck

P2116

Sigma-Aldrich

吡非尼酮

≥97% (HPLC), powder, antifibrotic agent

别名:

5-甲基-1-苯基-2-(1H)-吡啶酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H11NO
CAS号:
分子量:
185.22
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

吡非尼酮, ≥97% (HPLC)

品質等級

化驗

≥97% (HPLC)

形狀

powder

溶解度

H2O: >10 mg/mL at 60 °C (warming for 30 minutes)
DMSO: >20 mg/mL

起源

Shionogi

SMILES 字串

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChI 密鑰

ISWRGOKTTBVCFA-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

吡非尼酮(5-甲基-1-苯基-2-[1H]-吡啶酮)是合成的吡啶 衍生物。

應用

吡非尼酮用于:
  • 作为兔的术后滴眼剂,分析其抗纤维化作用,改进青光眼滤过手术
  • 作为抗瘢痕形成剂,检查其是否影响兔植入青光眼引流装置(GDD)后的异物反应
  • 在人眼眶成纤维细胞(hOF)原代培养物中测试其抗纤维化潜力
  • 作为肿瘤坏死因子(TNFα)抑制剂,研究其在缺氧中的作用

生化/生理作用

吡非尼酮可抑制胶原生成和成纤维细胞增殖。在多种肺纤维化动物模型和临床试验中显示出抗纤维化和抗炎属性。
吡非尼酮用于治疗特发性肺纤维化(IPF)。有助于减少肺功能下降引起的衰弱,延长无进展生存期。吡非尼酮可抑制人Tenon′s 囊成纤维细胞胶原蛋白的增殖和收缩。

特點和優勢

该化合物由 Shionogi 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表,请点击此处

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Stahnke T, et al.
Testing, 12(2), e0172592-e0172592 (2017)
Peyman Bizargity et al.
Transplantation, 94(2), 114-122 (2012-06-30)
Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on
Natalie J Carter
Drugs, 71(13), 1721-1732 (2011-09-10)
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower
Huzaifa I Adamali et al.
Drug design, development and therapy, 6, 261-272 (2012-10-12)
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门